GMP compliance is not the same as QMS coherence under INVIMA's audit framework. Learn what INVIMA evaluates in a quality system audit in Colombia and how to pre…
ANVISA's biologics registration pathway diverges from FDA and EMA at key points. Here are the 10 questions foreign manufacturers ask most — answered.
Explore medicinal product lifecycle management in South Korea, including MFDS post-approval changes, renewals, GMP compliance, and CTD requirements.
Saudi drug approvals are increasing rapidly. Learn how pharmaceutical companies can strengthen their SFDA submission strategy for faster approvals in 2026.
The ANVISA API pathway diverges from FDA and EMA at three critical points. Here is what foreign manufacturers need to understand before submitting.
Learn the API registration process in the Philippines, including FDA requirements, ACTD dossier submission, and post-approval compliance steps.
Explore the API registration process in Malaysia, including NPRA requirements, ACTD dossier submission, and compliance considerations.
Learn how MFDS South Korea regulates drug approvals, GMP compliance, pharmacovigilance, and post-market activities.
This blog talks about Health Canada’s eCTD deadline and key tips to ensure successful regulatory submissions.
This blog talks about FDA’s 21 CFR 820 amendment, aligning with ISO 13485 to harmonize QMS for medical devices.
The New Reality of Chemical Compliance Inspections: What Regulators Are Really Looking ForChemical companies are facing a different kind of scrutiny these da...
Learn how regulators review SDSs, hazard classifications, labels, and product claims during inspections. Improve audit readiness and compliance
Explore Jordan’s abridged drug registration pathway, key requirements, approval process, and Regulatory considerations for 2026
Updated EU CLP Rules: A Practical Breakdown for Chemical BusinessesThe EU has revised its Classification, Labelling and Packaging (CLP) Regulation again, and...
Learn how the UAE’s transfer of 44 pharmaceutical services from MOHAP to Emirates Drug Establishment impacts product registration, pricing, pharmacovigilance, a…
JFDA PIC/S membership impact on Jordan pharma boosts GMP alignment, reduces inspections, strengthens compliance, exports and global market access.
What FDA and EMA experience doesn't prepare regulatory teams for in a COFEPRIS NCE filing — and why that gap surfaces at the worst possible moment.
Your PV program may have been compliant when you built it. Here's why that's no longer enough — and what COFEPRIS actually evaluates today.
Global biologics dossiers regularly face friction at INVIMA — not because they are incomplete, but because they are not locally interpreted. Learn what dossier …
Learn how pharma companies can meet ALCOA+ data integrity requirements across GMP systems and prepare for global inspections with expert support from Freyr.